Resources & Guides

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Complete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

The ultimate retatrutide resource hub. Learn about this investigational triple-agonist, its remarkable Phase 2 results, dosing schedules, microdosing protocols, and use our free calculator to plan your journey.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

Retatrutide side effects guide: nausea, diarrhea, and other GI symptoms from Phase 2 clinical trial data, plus management strategies.

Everything you need to know about tirzepatide dosing: dual-agonist mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and dosing calculator.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

Zepbound side effects guide: nausea 25-29%, diarrhea 19-23%, symptom timeline, serious warnings, and practical management tips for weight loss patients.

Tirzepatide side effects guide: nausea, diarrhea, and other GI symptoms from clinical trial data, plus practical management tips.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

One chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.

Mounjaro (tirzepatide) treats type 2 diabetes by activating two incretin receptors at once. Here is the organ-level physiology, the SURPASS-1 evidence behind its 2022 FDA approval, and how it compares to Ozempic in head-to-head trials.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides, why compounded retatrutide is not a lawful option, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

SURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Free tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Retatrutide is the first triple agonist that activates GIP, GLP-1, and glucagon receptors at once. How each receptor contributes to weight loss, why it outperforms single and dual agonists, and what the clinical data shows.

While tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.